🇺🇸 🇹🇼 🇺🇦 🇮🇱

Great steve usdin commentary: 'The point of accelerated approval is not perfection; it’s to allow risk-taking when there’s evidence that a therapy is reasonably likely to benefit patients who are suffering from a serious condition.'

Thanks for elevating, Daphne. What I'm seeing in the comments is people reacting to what they think is unfair but trying to apply legal arguments. We cover the legal arguments in the article... but we don't defend the practice on the basis of its legality.

It is legal, that's

In honor of Patriots’ day (a festive New England thing), Sarah Reed and I put out a piece on Private Investments in Patriotic Equities (PIPEs) and confidential disclosure of data.

rapport.bio/all-stories/ob…

US support for Israel’s security must be immediate & ironclad.

The president is doing the right thing.

Mr Speaker: your turn. Come back from Mar-a-Lago and put the Israel & Ukraine bill on the floor on Monday.

Once again, plain english of how insurance and innovation are supposed to work together. Truth in insurance is good policy. Good to see it being discussed in Congress.

No Patient Left Behind I Am Biotech PhRMA The Economist BioCentury

Exactly. When insurance says they cover something, that should mean that it’s affordable to the patient. If they can’t afford it, then insurance wasn’t honest about covering it.

This is the right discussion for Congress to be having.

No Patient Left Behind I Am Biotech PhRMA The Economist

Small companies would absolutely not be able to get seed funding if we had to believe that the ONLY way to generate a return would be to build it into a profitable standalone company. That takes critical mass. Pharma already has it. Wasteful not to make use of it.

Movie studies don’t need to charge for movies because they aren’t even ones who write scripts… and writers who do barely earn anything. So don’t worry about price controlling movies. Hollywood will still remain creative.

Sound dumb? It is.

Wapo is smarter than this but thinks

Indeed, failure of society to harvest the benefits of the biotech social contract… specifically failure to make PBMs make good use of what the FDA and industry delivered (biosimilars).

Several fixes… but contractual genericization is probably easiest.

No Patient Left Behind

Pharmas now attempting to “negotiate” with CMS. During M&A discussion, sides can point to NPV assumptions to argue for particular share prices. Equivalent for a drug price is a GCEA, which estimates societal value of a drug. You know NPV… do you know GCEA? More on that at

NPLB applauds new 'Zero Copay' health plan mandate to prioritize the health & well-being of all insured Americans. The FTC will require all health plans to charge zero copays for prescribed medicines or face dissolution. Read the full announcement here:
nopatientleftbehind.docsend.com/view/bur6s3n6q…

The FTC has finally called insurance out for false advertising. Indeed, if you say you offer health insurance, you can’t then put appropriate treatment out of reach with high out of pocket costs.

Good work, No Patient Left Behind

nopatientleftbehind.docsend.com/view/bur6s3n6q…

I Am Biotech PhRMA Aetna Humana

After slight delay due to market downturn, RA Capital is proud to unveil its long planned suite of biotech ETFs to democratize biotech investing.

We can make cures as long as policy doesn’t undermine. We need insurance reform, not price controls.

prnewswire.com/news-releases/…

I would like a world where the FDA can adjudicate the clinical meaningfulness of any product, followed by every payor deciding if it’s worth covering (given their read of the priorities and values of their customer base), followed by every physician deciding if it’s appropriate